MRK – Merck & Company, Inc.
Healthcare | Drug Manufacturers - General | Website
Quick Stats
Trend Overview
MRK is in a well-structured bull trend. All major signals are aligned: positive swing trend, rising momentum over 9 days, a fully aligned moving average stack, a golden cross in place, and trend strength confirmed by ADX at 89.0. This is the type of environment where trend-following strategies carry a structural edge.
The trend is your friend here. As long as momentum strength continues to hold or rise, the path of least resistance remains higher. Manage the trade with a trailing stop rather than a fixed target.
Options Signal Highlight
Latest MRK Reports
MRK Price Chart
Technical Trend Analysis
As of 21.08.2026 · Close: $152.55 · ATR14: $2.89
MRK is in a well-structured bull trend. All major signals are aligned: positive swing trend, rising momentum over 9 days, a fully aligned moving average stack, a golden cross in place, and trend strength confirmed by ADX at 89.0. This is the type of environment where trend-following strategies carry a structural edge.
The trend is your friend here. As long as momentum strength continues to hold or rise, the path of least resistance remains higher. Manage the trade with a trailing stop rather than a fixed target.
| Indicator | Signal | Detail |
|---|---|---|
| Swing Trend | ▲ Long | Primary directional bias |
| Momentum | ▲ Up · 9d | Strength: 1.50 – Rising |
| Trend Strength (ADX) | 89.0 – Strong | ADX38: 41.2 |
| Volatility (HV30) | 41.4% – Rising | HV90: 35.0% | HV180: 29.5% |
| Vola Compression | None | Normal range |
| MA Structure | Golden Cross ✓ | Stack: Fully aligned – bullish stack |
| EMA21 Distance | 5.74 ATR ↑ | EMA21: $133.80 |
| GD200 Extension | 11.2 ATR – Exhausted | GD20: 4.7 | GD50: 6.6 | GD100: 8.6 |
Monthly Performance History
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010 | 3.18 | -3.68 | 1.26 | -7.12 | -4.47 | 5.45 | 0.05 | 0.25 | 4.42 | -0.81 | -4.93 | 3.90 | 1.61 |
| 2011 | -7.98 | -4.18 | 2.88 | 8.70 | 1.23 | -1.56 | -4.14 | -1.01 | 0.57 | 9.28 | 4.97 | 6.95 | 9.57 |
| 2012 | -0.09 | -1.20 | 2.76 | 1.87 | -4.53 | 13.52 | 5.53 | -2.78 | 5.28 | 0.92 | -3.56 | -7.00 | 11.37 |
| 2013 | 4.61 | 2.16 | 4.70 | 6.00 | 2.20 | -3.25 | 3.97 | -2.66 | 1.75 | -7.48 | 10.18 | 0.65 | 25.60 |
| 2014 | 7.02 | 9.41 | 1.41 | 3.88 | -2.93 | 0.63 | -3.02 | 5.84 | -0.13 | -1.30 | 2.52 | -5.44 | 18.25 |
| 2015 | 5.41 | -3.86 | -1.09 | 4.74 | 1.72 | -5.58 | 2.36 | -8.80 | -5.18 | 10.69 | -3.79 | -2.37 | -4.55 |
| 2016 | -3.45 | -1.08 | 3.11 | 2.12 | 1.73 | 3.11 | 1.24 | 7.04 | -0.04 | -6.08 | 3.20 | -2.36 | 15.81 |
| 2017 | 3.06 | 6.06 | -3.35 | -1.79 | 4.39 | -1.06 | -0.60 | -0.09 | 1.03 | -14.66 | -0.12 | 1.56 | -3.59 |
| 2018 | 5.41 | -9.44 | 2.32 | 10.49 | 2.68 | 1.00 | 8.95 | 4.73 | 5.13 | 2.92 | 8.51 | -2.88 | 40.08 |
| 2019 | -1.54 | 6.33 | 2.55 | -5.52 | 0.63 | 5.18 | -2.08 | 3.32 | -2.20 |
T 3.66 |
T 2.63 |
5.21 | 23.59 |
| 2020 | -7.17 | -12.34 | -4.68 |
T 7.52 |
3.93 |
T -2.02 |
T 2.70 |
3.32 | -1.04 | -7.88 |
T 4.80 |
1.10 | -8.30 |
| 2021 |
T -4.81 |
-6.13 |
T 7.45 |
-3.36 |
T -0.11 |
9.35 | -1.44 |
T 0.14 |
-0.53 |
T 8.18 |
-14.72 | 3.94 | 2.81 |
| 2022 |
T 6.00 |
-6.52 |
T 8.45 |
6.19 | 5.00 |
T 0.84 |
-3.33 |
T -3.58 |
-0.39 |
T 15.60 |
10.38 | 1.72 | 48.97 |
| 2023 | -3.36 |
T -0.69 |
0.45 |
T 6.06 |
-5.10 |
T 4.71 |
-6.72 |
T 3.51 |
-6.27 | 0.15 | -0.36 |
T 5.37 |
8.28 |
| 2024 | 6.66 | 0.61 |
T 3.93 |
-1.35 | -2.53 | -3.60 | -11.55 | 4.07 |
T -2.59 |
-10.82 | -0.24 | -1.12 | -12.15 |
| 2025 | -0.35 | -7.56 |
T -3.64 |
-2.20 | -7.71 |
T 3.82 |
-4.51 |
T 6.09 |
-1.81 |
T -4.60 |
27.08 | 3.37 | 6.14 |
| 2026 | 3.59 | 9.22 | -0.92 |
T -9.65 |
T 5.85 |
11.57 | 3.85 | 19.39 | 43.31 |
T A T badge marks a Trendchange signal in that month. Hover for entry price.
Trendchange Signal History
The last 10 Trendchange signals for MRK:
| Date | Entry Price | Days Held | +10d | +20d | +30d | +60d |
|---|---|---|---|---|---|---|
| 22.05.26 | $122.41 | 21d | -1.32% | -6.14% | +5.27% | +24.62% |
| 07.04.26 | $119.28 | 6d | -1.16% | -1.16% | -1.16% | +0% |
| 06.04.26 | $120.85 | 0d | +0% | +0% | +0% | +0% |
| 02.10.25 | $89.51 | 31d | -6.03% | -3.27% | +2.17% | +43.56% |
| 15.08.25 | $84.21 | 15d | -1.19% | +1.12% | +1.12% | +0% |
| 12.06.25 | $81.82 | 20d | -3.65% | +1.88% | +3.53% | +4.07% |
| 06.03.25 | $94.00 | 12d | +0.02% | -1.8% | -1.8% | -9.88% |
| 20.09.24 | $117.17 | 4d | -1.31% | -1.31% | -1.31% | -21.22% |
| 27.03.24 | $131.75 | 9d | -3.8% | -4.22% | -1.67% | -12.24% |
| 05.12.23 | $106.23 | 53d | -0.18% | +8.04% | +11.59% | +23.2% |
Signal Statistics – Historical Edge
Calculated edge for MRK: 11.62%
| Range | N | 10d | 20d | 30d | 60d | Signal |
|---|---|---|---|---|---|---|
| 5-7% | 1 | +5.74% | +9.64% | +15.19% | +27.07% | Hold |
| 3-5% | 7 | +3.74% | +4.05% | +4.6% | +12.03% | Hold |
| 1-3% | 10 | +1.89% | +3.6% | +4.3% | +3.46% | Close |
| 0-1% | 3 | +0.07% | -1.13% | -1.13% | -1.62% | Close |
| -1-0% | 7 | -0.51% | +0.36% | +0.83% | +3.31% | Neg |
| -3-1% | 10 | -1.69% | -0.03% | +1.77% | +1.06% | Neg |
| -5-3% | 3 | -3.74% | +1.33% | +1.69% | -2.15% | Neg |
| -7-5% | 3 | -5.81% | -5.12% | -3.42% | +14.52% | Neg |
Signal data as of August 21, 2026
Options Metrics
Gamma Exposure Timeline
Key GEX levels, Max Pain, and unusual activity across weekly and monthly expirations, plotted around the current spot price.
Key GEX levels, Max Pain, Anchor, Ceiling and unusual activity across 14-30 DTE, plotted around the current spot price.
Put and call pins mark strikes where dealer gamma exposure concentrates. The GEX flip strike is where dealer hedging shifts from stabilizing (positive gamma) to amplifying (negative gamma) price moves. Max Pain is the strike where the most options expire worthless. Dashed markers flag unusual options activity. Learn how to use these signals in our options strategy guides →
Strategy Setups – You Decide
Based on current options data, 2 setups match the current conditions. Each strategy has different risk/reward characteristics – the final decision is always yours.
All setups above are personal trade journal observations derived from options flow data. This is not financial advice. The decision to trade, and which strategy to use, is entirely yours.
View full options flow data and historical signals on the Options Flow Analysis Overview →
Valuation
| Metric | Value |
|---|---|
| Market Cap | $335.14 B |
| PE Ratio (TTM) | 108.67 |
| Forward PE | 14.21 |
| PEG Ratio | 12.72 |
| EV/EBITDA | 13.21 |
| Price/Sales | 5.03 |
| Price/Book | 8.00 |
| Beta | 0.21 |
Profitability
| Metric | Value |
|---|---|
| Gross Margin | 75.90% |
| Operating Margin | -0.24% |
| Net Margin | 4.77% |
| ROE | 6.96% |
| ROA | 11.87% |
Dividends
| Metric | Value |
|---|---|
| Annual Dividend | $3.4 |
| Forward Yield | 251.00% |
| Payout Ratio | 268.80% |
| Dividend Date | 2026-10-06 |
Analyst Consensus (26 Analysts)
| Metric | Value |
|---|---|
| Median Target | $142 |
| High Target | $155 |
| Low Target | $105 |
About Merck & Company, Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
ETF Holdings
Merck & Company, Inc. is included in 3 ETFs tracked by StockBotty.